Project profile — COVAX Advance Market Commitment for COVID-19 Vaccine

• Africa, regional (50.00%)
• America, regional (20.00%)
• Asia, regional (25.00%)
• Oceania, regional (2.00%)
• Europe, regional (3.00%)

• Health: COVID-19 control (12264) (100.00%)

• Gender equality (not targeted)
• Environmental sustainability (cross-cutting) (not targeted)
• Participatory development and good governance (not targeted)
• Trade development (not targeted)
• Biodiversity (not targeted)
• Climate change mitigation (not targeted)
• Climate Change Adaptation (not targeted)
• Urban issues (not targeted)
• Desertification (not targeted)
• Children's issues (not targeted)
• Youth Issues (not targeted)
• Disaster Risk Reduction(DRR) (not targeted)
• Disability (not targeted)
• Indigenous Issues (not targeted)
• Nutrition (not targeted)
• ICT as a tool for development (not targeted)

This project aims to strengthen COVID-19 response and recovery in the Advance Market Commitment 92 (AMC-92) eligible low-and lower-middle-income economies. It reduces COVID-19 related mortality and morbidity, particularly amongst vulnerable and priority-use populations, through increased access to vaccines. Project activities include (1) supporting the COVAX Advance Market Commitment in the procurement of COVID-19 vaccines for the AMC 92 eligible economies; and (2) supporting the Pandemic Vaccine Pool in the procurement of vaccines for surges or future pandemic threats, vaccine delivery activities, and ancillary costs for donated vaccine doses.

The expected outcomes of this project include: (1) increase access to vaccines for all AMC 92 economies, focusing on primary series and boosters, as necessary, to advance toward national targets for high-priority populations, including healthcare workers, older adults and the most vulnerable; and (2) increase the number of vaccines provided to the AMC 92 eligible economies.

Results achieved as of June 2023 include: (1) COVAX delivered over 1.754 billion vaccines to the Advance Market Commitment 92 low and lower-middle-income economies; and (2) estimates show 75% of deaths averted in Advance Market Commitment 92 low-income countries are attributable to COVAX-supported doses.

• Proactive disclosure
• Related activities:
• COVAX Advance Market Commitment for COVID-19 vaccines
• COVAX Advance Market Commitment for COVIS-19 vaccine